Business
ORYZON to Participate in Upcoming Events in September and October
MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events: Drug Discovery Innovation Programme, September 25-26Location: Intercontinental Hotel, Barcelona, Spain Paris Midcap Event 2025, September 30-October 1Location: Four Seasons George V, Paris, France BME Investor Acce
About this update from Oryzon Genomics Sa
[{"type":"image","alt":"Oryzon Genomics, S.A.","displaySize":"","headline":null,"caption":"Oryzon Genomics, S.A.","className":"","disableSlideshowImg":false,"size":{"original":{"width":182,"height":70,"url":"https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/cNdaqSWVXmpOQnfrePXGFw--/YXBwaWQ9aGlnaGxhbmRlcjt3PTM2MDtoPTEzODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/371936053f3f3aceeaf8ca929a3547e2","width":182,"height":70}},"lazy":false},{"type":"text","content":"MADRID and CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A. (ISIN Code: ES0167733015, ORY), a clinical-stage biopharmaceutical company and a European leader in epigenetics, announced today that its management will participate at the following upcoming events:","length":285,"tagName":"p"},{"type":"text","content":"Drug Discovery Innovation Programme, September 25-26Location: Intercontinental Hotel, Barcelona, Spain","length":103,"tagName":"p"},{"type":"text","content":"Paris Midcap Event 2025, September 30-October 1Location: Four Seasons George V, Paris, France","length":94,"tagName":"p"},{"type":"text","content":"BME Investor Access Event 2025, October 7Location: Maison de la Chimie, Paris, France","length":86,"tagName":"p"},{"type":"text","content":"BIOSPAIN 2025, October 7-9Location: Fira de Barcelona – Montjuïc, Barcelona, Spain","length":83,"tagName":"p"},{"type":"text","content":"25th Sachs Annual Biotech in Europe Forum 2025, October 8-9Location: Mövenpick Hotel, Basel, SwitzerlandPresentation type: Company presentationPresentation date and time: October 8, 13:45 CET","length":194,"tagName":"p"},{"type":"text","content":"Oryzon management will be available for one-on-one meetings during the conferences.","length":83,"tagName":"p"},{"type":"text","content":"About OryzonFounded in 2000 in Barcelona, Spain, Oryzon (ISIN Code: ES0167733015) is a clinical stage biopharmaceutical company and the European leader in epigenetics, with a strong focus on personalized medicine in CNS disorders and oncology. Oryzon’s team is composed of highly qualified professionals from the pharma industry located in Barcelona, Boston, and San Diego. Oryzon has an advanced clinical portfolio with two LSD1 inhibitors, vafidemstat in CNS (Phase III-ready) and iadademstat in oncology (Phase II). The compan...